Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CENTERA: Aflibercept Treat and Extend for Macular Edema in CRVO
NCT02800642Phase 4Completed
- Sponsor
- Bayer
- Start
- Jun 2016
- Primary completion
- Jul 2019
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 8
01
Overview
A Phase 4 trial of aflibercept in macular edema, sponsored by Bayer. Started Jun 2016; status: completed.
02
Drugs
aflibercept
03
Conditions
macular edema
Beyond the preview
Go deeper on NCT02800642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02800642.